Abstract Library

#4665 Prognostic value of systemic inflammatory parameters in neuroendocrine tumour patients treated with peptide receptor radionuclide therapy – Preliminary results

Introduction: PRRT (177Lu-Dotatate) is a therapeutic option for advanced NETs (neuroendocrine tumours). Systemic inflammatory parameters, such as NLR, PLR, SII, and other ratios derived from complete blood counts, are considered prognostic markers in NETs and other malignancies.

Conference:

Presenting Author: Maciejewski A

Authors: Maciejewski A, Komarnicki P, Musiałkiewicz J, Gut P, Ruchała M,

Keywords: neuroendocrine tumour, PRRT, systemic inflammatory parameter, PLR, prognostic biomarker,

#4648 Analysis of presentation and outcomes of mixed adenoneuroendocrine carcinoma (MANEC) – A single centre experience

Introduction: Mixed adenoneuroendocrine carcinoma (MANEC) is a rare neoplasm characterised by the coexistence of both adenocarcinoma and neuroendocrine carcinoma components. Due to its rarity, limited data exist regarding its clinical presentation, treatment strategies, and outcomes. This study provides an analysis of MANEC cases from a single centre, providing insights into its clinical features, diagnostic challenges, treatment strategies, and prognosis.

Conference:

Presenting Author: Khosla D

Authors: Khosla D, Kapoor R, Mehta A, Gupta R, Singh H,

Keywords: MANEC, mixed adenoneuroendocrine carcinoma, treatment,

#4610 The last 10 years – Single centre experience of gastrointestinal NEN

Introduction: Neuroendocrine neoplasms (NEN) are rare and heterogeneous, comprising 2% of all malignancies, with progressively increasing incidence. Most arise sporadically and the most frequent primary sites are gastrointestinal and lung.

Conference:

Presenting Author:

Authors: Corrêa Figueira C, Alves H, Bento A, Oliveira M, Garrido R,

Keywords: Neuroendocrine neoplasm, Gastrointestinal neuroendocrine tumour, Multidisciplinary team meeting, Retrospective, Single centre,

#4548 Carcinoid heart disease in patients with carcinoid syndrome and metastatic small intestinal neuroendocrine tumours: A single centre experience

Introduction: Carcinoid heart disease (CHD) is a significant complication of carcinoid syndrome (CS) in patients with small intestinal neuroendocrine tumours (SINET). Management is complex and more data is needed.

Conference:

Presenting Author:

Authors: Salman M, Waters M, Abbott C, Quinn M, O'Toole D,

Keywords: carcinoid heart disease, carcinoid syndrome, NET, neuroendocrine tumour, small intestinal NET,

#4485 Inpatient admissions for hormone secretion management in patients with neuroendocrine neoplasms (NEN) treated with [177Lu]Lu-DOTA-Octreotate (LuTate) therapy over a 4.5 year period at a single high volume treatment centre

Introduction: LuTate therapy is an effective treatment for patients with somatostatin receptor expressing NEN. However, patients (pts) with functional tumours may develop an acute flare of symptoms during or after PRRT.

Conference:

Presenting Author: Kong G

Authors: Neeson L, Boehm E, Chiang C, Michael M, Sachithanandan N,

Keywords: PRRT, NET, high-risk, flare, outcomes, NEN, single centre,